

TrkC receptor antagonists - Pipeline Insight, 2022

<https://marketpublishers.com/r/T80BF09B69F8EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: T80BF09B69F8EN

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "TrkC receptor antagonists - Pipeline Insight, 2022" report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in TrkC receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

TrkC receptor antagonists Understanding

TrkC receptor antagonists: Overview

Trk receptors are a family of tyrosine kinases that regulates synaptic strength and plasticity in the mammalian nervous system. Trk receptors affect neuronal survival and differentiation through several signaling cascades. However, the activation of these receptors also has significant effects on functional properties of neurons. TrkC is ordinarily activated by binding with NT-3 and has little activation by other ligands. (TrkA and TrkB also bind NT-3, but to a lesser extent). TrkC is mostly expressed by proprioceptive sensory neurons. The axons of these proprioceptive sensory neurons are much thicker than those of nociceptive sensory neurons, which express trkA.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence TrkC receptor antagonists R&D. The therapies under development are focused on novel approaches for TrkC receptor antagonists.

TrkC receptor antagonists Emerging Drugs Chapters

This segment of the TrkC receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

TrkC receptor antagonists Emerging Drugs

Ensartinib: Betta Pharmaceuticals

Ensartinib hydrochloride is a potent and highly selective next-generation ALK inhibitor with independent intellectual property rights, and it is developed jointly by Betta Pharmaceuticals Co., Ltd. and its subsidiary Xcovey Holding, Inc. (Xcovery). Ensartinib hydrochloride is another product following the EGFR-TKI in Betta's lung cancer pipeline, and it is expected to be the first innovative targeted drug for lung cancer which is launched globally by a Chinese company. Ensartinib (X-396) is a novel II generation, aminopyridazine-based ALK-TKI able to inhibit both wild-type ALK and all evaluated ALK variants (F1174, C1156Y, L1196M, S1206R, T1151, and G1202R mutants) with in vitro IC50 of

Contents

Introduction

Executive Summary

TrkC receptor antagonists: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

TrkC receptor antagonists – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Reprotrectinib: Turning Point Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Entrectinib: Roche

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I and I/II)

Comparative Analysis

PBI 200: Pyramid Biosciences

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis
KFP H013: Jiangsu Carephar Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
TrkC receptor antagonists Key Companies
TrkC receptor antagonists Key Products
TrkC receptor antagonists- Unmet Needs
TrkC receptor antagonists- Market Drivers and Barriers
TrkC receptor antagonists- Future Perspectives and Conclusion
TrkC receptor antagonists Analyst Views
TrkC receptor antagonists Key Companies
Appendix

I would like to order

Product name: TrkC receptor antagonists - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/T80BF09B69F8EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T80BF09B69F8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970